Evidence map›Paper›PMID 36741486›Full record

ArticleCaspian journal of internal medicine2023

Effect of vitamin A on recovery from the acute phase of multiple sclerosis-related optic neuritis, double-blind, randomized, placebo-controlled trial.

Shiva Rahimi-Dehgolan, Maryam Masoudi, Shahram Rahimi-Dehgolan, Amir Reza Azimi, Mohammad Ali Sahraian, Seyed Mohammad Baghbanian, Abdorreza Naser Moghadasi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Caspian journal of internal medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shiva Rahimi-DehgolanMultiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical sciences, Tehran, Iran.
Maryam MasoudiMultiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical sciences, Tehran, Iran.
Shahram Rahimi-DehgolanPhysical Medicine and Rehabilitation Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Amir Reza AzimiMultiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical sciences, Tehran, Iran.
Mohammad Ali SahraianMultiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical sciences, Tehran, Iran.
Seyed Mohammad BaghbanianDepartment of Neurology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Abdorreza Naser MoghadasiMultiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRMazandaran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Optic neuritis (ON) is one of the main neuro-ophthalmic presentations of multiple sclerosis (MS), and it causes optic nerve atrophy and axonal loss. However, so far, there is no effective treatment to improve long-term outcomes. Methods: In a double-blind placebo-controlled randomized clinical trial, 50 patients with MS-related ON were allocated into two arms (24 in the control group and 26 in the intervention group) receiving either 25000IU retinyl palmitate or an identical placebo for six months. Visual evoked potential (VEP), visual acuity, and the retinal nerve fiber layer (RNFL) thickness were evaluated and compared before and after the treatment. Results: RNFL thickness reduction in the affected eyes at sixth month compared to the baseline were 14.81 and 19.46 μm, in the intervention and control groups, respectively (P=0.017). However, VitA therapy did not affect visual acuity and VEP. Conclusion: Vitamin A supplementation in the patients with acute ON in MS could lessen optic nerve axonal loss.

Indexed as

Axonal damageMultiple sclerosisOptic neuritisVitamin A

Identifiers

PMID36741486
PMCPMC9878905
OpenAlexW4319295357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.